|本期目录/Table of Contents|

[1]吴文昊,王 康,朱 端,等.凝血功能异常对新冠肺炎重症患者的预后意义[J].中华肺部疾病杂志,2022,(02):187-191.[doi:10.3877/cma.j.issn.1674-6902.2022.02.010]
　Wu Wenhao,Wang Kang,Zhu Duan,et al.Prognostic significance of abnormal coagulation function in critically ill patients of COVID-19[J].,2022,(02):187-191.[doi:10.3877/cma.j.issn.1674-6902.2022.02.010]
点击复制

凝血功能异常对新冠肺炎重症患者的预后意义(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2022年02期
页码:
187-191
栏目:
论著
出版日期:
2022-04-20

文章信息/Info

Title:
Prognostic significance of abnormal coagulation function in critically ill patients of COVID-19
作者:
吴文昊; 王 康; 朱 端; 张厚丽; 陈俞坊; 周向东
400038 重庆,陆军(第三)军医大学第一附属医院呼吸与危重症医学科
Author(s):
Wu Wenhao;  Wang Kang;  Zhu Duan;  Zhang Houli;  Chen Yufang;  Zhou Xiangdong.
Institute of Respiratory Diseases, Department of Respiratory, the First Affiliated Hospital, Army Military Medical University, Chongqing 400038, China
关键词:
新型冠状病毒肺炎;  凝血功能;  凝血酶原时间;  重症患者
Keywords:
Coronavirus disease 2019;  Coagulation function;  Prothrombin time;  Critically ill patient
分类号:
R563
DOI:
10.3877/cma.j.issn.1674-6902.2022.02.010
摘要:
目的 分析新型冠状病毒肺炎(corona virus disease 2019, COVID-19)患者凝血功能的临床特征,及其对重症化的预测和预后意义。方法 收集2020年2月至4月在武汉泰康同济医院确诊的COVID-19患者356例的凝血功能指标,分析其与COVID-19重症化、预后的关联。结果 356例患者入院时,普通型200例,重型118例,危重38型例。出院时,普通型190例,重型107例,危重型59例。患者凝血酶原时间(prothrombin time, PT)越长、D二聚体越高(D-dimer, DD)D-二聚体越高(D-dimer, D-dimer)、血小板计数越低,诊断为重型和危重型的概率越高(P<0.05)。年龄显著影响重症化(P<0.05,OR=1.054),年龄每增加1,重症化概率提升0.054倍。PT能显著影响重症化(P<0.05,OR=1.245),PT每提升1,重症化概率提升0.245倍。结论 高龄、心血管系统基础疾病、PT延长、D二聚体升高,是COVID-19患者重症化的高危因素和预测、预后重要因素。
Abstract:
Objective To analyze the clinical characteristics of blood coagulation function in patients with COVID-19 and its significance in predicting and prognosis of severe symptoms. Method The coagulation function data of COVID-19 patients diagnosed in Wuhan Taikang Tongji Hospital from February to April 2020 were collected and their correlation with the severity and prognosis of COVID-19 patients. Results A total of 356 patients who met the criteria were collected. at the time of admission, there were 200 cases of common type, 118 cases of severe type and 38 cases of critical type. At discharge, there were 190 cases of common type, 107 cases of severe type and 59 cases of critical type. The critically ill patients with significantly elevated D-dimer and heparin intervention were defined as heparin group, and the critically ill patients with significantly elevated D-dimer without heparin intervention were defined as non-heparin group. There were 53 cases in heparin group and 41 cases in non-heparin group. The longer the prothrombin time(PT), the higher the D-dimer(DD), the higher the D-dimer(D-dimer)and the lower the platelet count, the higher the probability of diagnosis of severe and critical patients. Age could significantly affect the severity of symptoms(P<0.05, OR=1.054), every 1 increase in age increases the probability of severe illness by 0.054 times. PT can significantly affect the severity of symptoms(P<0.05, OR=1.245), for every 1 increase in PT, the probability of severe illness increases by 0.245 times. Conclusion COVID-19 patients with advanced age, basic cardiovascular diseases, prolonged PT and elevated D-dimer are all high risk factors for severe illness and important factors for predicting the prognosis of critically ill patients.

参考文献/References:

1 国家卫生健康委员办公厅. 国家中医药管理局办公室关于印发新型冠状病毒肺炎诊疗方案( 试行第六版)的通知国卫办疾控函〔2020〕204 号. 2020-03-07
2 Vincent J. COVID-19: it's all about sepsis[J]. Future Microbiology, 2021, 16(3): 131-133.
3 Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19[J]. Lancet, 2020, 395(10234): 1417-1418.
4 Pons S, Fodil S, Azoulay E, et al. The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection[J]. Critical Care, 2020, 24(1): 353.
5 Wichmann D, Sperhake JP, Lutgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: A prospective cohort study[J]. Ann Intern Med, 2020, 173(4): 268-277.
6 Dolhnikff M, Duarte Neto AN, Almeida Monteiro RA, et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19[J]. J Thromb Haemost, 2020, 18(6): 1517-1519.
7 Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia[J]. J Thromb Haemost, 2020, 18(4): 844-847.
8 Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19[J]. J Thromb Haemost, 2020, 18(5): 1023-1026.
9 Wu Z, Mcgoogan JM. Characteristics of and important lessons from the coronavirus disease 2019(COVID-19)outbreak in China: Summary of a report of 72314 cases from the Chinese center for disease control and prevention[J]. JAMA, 2020, 323(13): 1239-1242.
10 Puelles VG, Lutgehetmann M, Lindenmeyer MT, et al. Multiorgan and Renal Tropism of SARS-CoV-2[J]. N Engl J Med, 2020, 383(6): 590-592.
11 Roumenina LT, Rayes J, Frimat M, et al. Endothelial cells: source, barrier, and target of defensive mediators[J]. Immunolog Rev, 2016, 274(1): 307-329.
12 Daniel AE, van Buul JD. Endothelial junction regulation: A prerequisite for leukocytes crossing the vessel wall[J]. J Inn Immun, 2013, 5(4): 324-335.
13 Teijaro JR, Walsh KB, Cahalan S, et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection[J]. Cell, 2011, 146(6): 980-991.
14 Paz OM, Riquelme JA, Garcia L, et al. Counter-regulatory renin-angiotensin system in cardiovascular disease[J]. Nat Rev Cardiol, 2020, 17(2): 116-129.
15 Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function[J]. Nature, 2002, 417(6891): 822-828.
16 Shaw RJ, Bradbury C, Abrams ST, et al. COVID-19 and immunothrombosis:emerging understanding and clinical management[J]. Br J Haematol, 2021, 194(3): 518-529.
17 Perico L, Benigni A, Casiraghi F, et al. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19[J]. Nat Rev Nephrol, 2021, 17(1): 46-64.
18 Lin GL, Mcginley JP, Drysdale SB, et al. Epidemiology and Immune Pathogenesis of Viral Sepsis[J]. Front Immunol, 2018, 9: 2147.
19 Mcgonagle D, O'Donnell JS, Sharif K, et al. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia[J]. Lancet Rheumatol, 2020, 2(7): e437-e445.
20 Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020, 8(4): 420-422.
21 Bachler M, Bosch J, Sturael DP, et al. Impaired fibrinolysis in critically ill COVID-19 patients[J]. Br J Anaesth, 2021, 126(3): 590-598.
22 Eegelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity[J]. Nature Rev Immunol, 2013, 13(1): 34-45.
23 Llitjos JF, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients[J]. J Thromb Haemost, 2020, 18(7): 1743-1746.
24 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223): 497-506.
25 Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China[J]. JAMA, 2020, 323(11): 1061-1069.
26 Azevedo RB, Botelho BG, Hollanda J, et al. Covid-19 and the cardiovascular system: a comprehensive review[J]. J Hum Hypertens, 2021, 35(1): 4-11.
27 Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy[J]. J Thromb Haemost, 2020, 18(5): 1094-1099.
28 Buijsers B, Yanginlar C, Maciej-Hulme ML, et al. Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients[J]. EBioMed, 2020, 59: 102969.
29 Poterucha TJ, Libby P, Goldhaber SZ. More than an anticoagulant: Do heparins have direct anti-inflammatory effects?[J]. Thromb Haemost, 2017, 117(3): 437-444.

备注/Memo

备注/Memo:
通信作者: 周向东, Email: xiangdongzhou@126.com
更新日期/Last Update: 2022-04-20